Anagliptin

Generic Name
Anagliptin
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C19H25N7O2
CAS Number
739366-20-2
Unique Ingredient Identifier
K726J96838
Background

Anagliptin is under investigation for the treatment of LDL Cholesterol, Coronary Disease, Diabetes Mellitus, Glycosylated Hemoglobin, and Dipeptidyl-Peptidase 4 Inhibitors.

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Korean Observational Study to Evaluate the Efficacy and Safety of Anagliptin Switching From Other DPP4is in type2 DM

First Posted Date
2020-02-13
Last Posted Date
2021-04-29
Lead Sponsor
JW Pharmaceutical
Target Recruit Count
2448
Registration Number
NCT04267601
Locations
🇰🇷

The Catholic University of Korea, Bucheon ST. Mary's hopsital, Bucheon, Korea, Republic of

Randomized Evaluation of Anagliptin Versus Sitagliptin On Low-density lipoproteiN Cholesterol in Diabetes Trial

First Posted Date
2015-01-05
Last Posted Date
2019-08-28
Lead Sponsor
Institute for Clinical Effectiveness, Japan
Target Recruit Count
353
Registration Number
NCT02330406
Locations
🇯🇵

Department of Cardiovascular Medicine, Tomishiro Central Hospital, Tomishiro, Okinawa, Japan

Efficacy and Safety of CWP-0403 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin Alone

Phase 3
Completed
Conditions
Type 2 Diabetes Mellitus
Interventions
Drug: Sitagliptin
Drug: Anagliptin
First Posted Date
2012-02-09
Last Posted Date
2014-05-14
Lead Sponsor
JW Pharmaceutical
Target Recruit Count
200
Registration Number
NCT01529541
Locations
🇰🇷

Kangbuk Samsung Hospital, Seoul, Korea, Republic of

A Study to Efficacy and Safety of CWP-0403 in Type 2 Diabetes Mellitus Patients

First Posted Date
2012-02-09
Last Posted Date
2013-01-04
Lead Sponsor
JW Pharmaceutical
Target Recruit Count
117
Registration Number
NCT01529528
Locations
🇰🇷

Kangbuk Samsung Hospital, Seoul, Korea, Republic of

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy